



Medical Grade Heart Attack Detection

Always with the patient

First Quarter 2023 Financial Results Conference Call

NASDAQ: BEAT

May 11, 2023

DISCLAIMERS

This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and plans and objectives of management for future operations, are forward-looking statements.

These statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "aims," "predicts," "potential," "seeks," "attempts," "poised" or "continues" or the negative of these terms or other similar words. These statements are only predictions.

The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Also, these forward-looking statements represent the Company's estimates and assumptions only as of the date of this presentation. The Company assumes no obligation to update any forward-looking statements after the date of this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other industry data. This data involves several assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, it cannot guarantee their accuracy or completeness.

In addition, projections, assumptions and estimates of its future performance and the future performance of the industries in which it operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by the Company. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see disclosures contained in HeartBeam's public filings with the SEC, including the "Risk Factors" in HeartBeam's Annual Report on Form 10-K, and which may be viewed at www.sec.gov.

HeartBeam AIMI™ and HeartBeam AIMIGo™ have not yet been evaluated by the FDA and are not approved for clinical use in the USA or other global geographies.

Agenda

- Introduction and Recent Announcements
- Strategic Focus and HeartBeam AIMiGo Update
- Financing and Financial Results
- Closing Summary

Branislav Vajdic

Robert Eno

Rick Brounstein

Branislav Vajdic



Branislav Vajdic, PhD
CEO & Founder

30 years of experience in technology development and senior management positions. At Intel, he was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs.



Robert Eno
President

28 years of experience with a proven track record of developing markets and commercializing disruptive medical technologies. During his career he has created go-to-market strategies for multiple breakthrough products and held senior marketing and sales leadership roles.



Rick Brounstein
CFO

30 years of experience in health technology senior management. During his career he has held positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager.

Key First Quarter 2023 and Subsequent Highlights

- Closed a secondary offering and registered direct offering for gross proceeds of \$26.5 million to enable company to execute on upcoming clinical, regulatory and commercial milestones, and extend cash runway into late 2024
- Adjusted strategic focus to enable timely delivery of HeartBeam's breakthrough ambulatory VECG products, the company's key future value drivers
- Strategic acquisition of substantially all assets from LIVMOR, a digital health solutions company, including FDA-cleared Halo+™ Atrial Fibrillation Detection System
- Appointed senior medical technology executive Robert Eno as President



Fundraising Activities

- Closed a secondary offering of \$25 million, followed by registered direct offering of \$1.5 million for a total of \$26.5 million
- Oversubscribed from initial \$15 million raise
- Public Ventures LLC acted as placement agent for the offering
- The funding will enable HeartBeam to execute on upcoming product development, clinical, and regulatory milestones, extending the cash runway into late 2024

2023 Strategic Focus

REGULATORY

- Immediate focus: obtaining FDA 510(k) clearance for the HeartBeam AIMIGo credit card-sized VECG device, followed by a second FDA clearance on the system's ability to synthesize an electrocardiogram (ECG).
- These clearances provide a key value creation path, enabling physicians to remotely monitor patients and immediately interpret any concerning cardiac events.

CLINICAL

- Demonstrate through clinical trials in 2023 the performance of the HeartBeam AIMIGo platform, which we believe is the most advanced ambulatory cardiac detection platform available. We believe this will drive clinical and patient adoption.
- Add world leading Key Opinion Leaders (KOLs) to our Medical Advisory Board to help guide our clinical and regulatory development. These Advisory Board members will be announced in the near future.

COMMERCIAL

- Shift the commercial launch until obtaining FDA clearance for 12-lead equivalence. Undertake an aggressive pre-commercial effort to define initial market segments and identify potential business partners.


INTELLECTUAL PROPERTY

- Continue aggressive development of our IP through our partnership with PatentVest, a unified technology development and patent law firm focused on creating IP leadership for development stage technology companies.
- The partnership is focused on the goal of creating clear leadership in the area of ambulatory VECG cardiac detection.

HeartBeam AIMIGo Updates

- FDA 510(k) submission for HeartBeam AIMIGo, Version 1 expected in May
- Submission is focused on the HeartBeam AIMIGo VECG hardware
- Version 2, which includes generation of a synthesized 12L ECG, will be submitted following clearance of the V1 system

HEARTBEAM AIMIGo FDA Product Development



*This timeline is for illustrative purposes only and is meant to portray a sequence of events, not their estimated timing.

Q1 2023 Financial Highlights

\$ in Thousands	Quarters ended March 31,	
	2023	2022
Operating Expenses:		
General & Administrative	\$2,475	\$1,414
Research & Development	1,681	734
Total Operating Expenses	4,156	2,148
Loss from Operations	(4,156)	(2,148)
Interest Income (Expense)	20	2
Other Income	-	-
Net loss	\$(4,136)	\$(2,146)
Cash & Cash Equivalents	\$990	

Projected Use of Proceeds


2023	In thousands
Clinical & Regulatory	\$2,000
Research & Development	\$8,000
Product	\$1,000
General & Administrative	\$4,000

Into Late 2024

Prepare for Commercialization, Working Capital and General Corporate Purposes	\$9,600
Total Use of Proceeds	\$24,600

Closing Summary

- Closed a secondary offering and registered direct offering for gross proceeds of \$26.5 million to enable company to execute on upcoming clinical, regulatory and commercial milestones, and extend cash runway into late 2024
- Adjusted strategic focus to enable timely delivery of HeartBeam's breakthrough ambulatory VECG products, the company's key future value drivers
- Key element of the strategic focus is the HeartBeam AIMIGo credit card-sized VECG device.



Q&A

Company

Rick Brounstein
Chief Financial Officer
HeartBeam, Inc.
ir@heartbeam.com

Investor Relations

Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us

Heart  Beam

www.heartbeam.com

2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050

